Karyopharm Therapeutics (KPTI) PT Lowered to $8 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $0.07 -22.22%
Rating Summary:
10 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
10 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $8.00 (from $12.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Rodman & Renshaw Downgrades Karyopharm Therapeutics (KPTI) to Neutral
- Clear Secure Inc (YOU) PT Raised to $80 at Goldman Sachs
- ArcBest Corp (ARCB) PT Lowered to $146 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
